- Home
- » Tags
- » Ficlatuzumab
Top View
- IUPAC Glossary of Terms Used in Immunotoxicology (IUPAC Recommendations 2012)*
- 2018 Medicines in Development for Cancer
- WO 2017/176762 Al 12 October 2017 (12.10.2017) P O P C T
- (INN) for Biological and Biotechnological Substances
- Phase I Study of Ficlatuzumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer
- PDF of Antibody News
- N° 18380 A61k 31/5377 (2018.01) A61p 35/02 (2018.01)
- Biotherapeutic Antibodies for the Treatment of Head and Neck Cancer
- ESMO 2012 Ficlatuzumab PKPD Poster
- Investigational Monoclonal Antibodies in the Treatment of Multiple Myeloma: a Systematic Review of Agents Under Clinical Development
- International Nonproprietary Names (INN) for Biological and Biotechnological Substances
- AVEO and Biodesix Announce Positive Results from Phase Ib Ficlatuzumab-Cytarabine Trial in Patients with Relapsed and Refractory AML
- Tumor Microenvironment and Immune Evasion in Head and Neck Squamous Cell Carcinoma ✉ Areeg Elmusrati1, Justin Wang1,2 and Cun-Yu Wang1,2
- Role and Therapeutic Targeting of the HGF/MET Pathway in Glioblastoma
- 2020 Medicines in Development ꟷ Cancer
- Compilation of Abstract Titles from ASCO Annual Meeting 2021 (Oral, Poster Discussion, Posters, Mains Track by Cancer Types Only)
- WO 2017/075107 Al 4 May 2017 (04.05.2017) P O P C T
- PET Imaging of Receptor Tyrosine Kinases in Cancer Weijun Wei1,2,Dalongni2, Emily B
- Personalizing Medicine in Head and Neck Squamous Cell Carcinoma: the Rationale for Combination Therapies
- Supplementary Tables and Figures Section 1. Distribution of CDR-H3
- Global Oncology Trend Report a Review of 2015 and Outlook to 2020
- Dysregulation of the Met Pathway in Non-Small Cell Lung Cancer: Implications for Drug Targeting and Resistance
- A Pharmacodynamic/Pharmacokinetic Study of Ficlatuzumab in Patients
- Emerging Drugs for Head and Neck Cancer
- Oncology Drugs in the Pipeline
- Microenvironment-Derived HGF Overcomes Genetically Determined Sensitivity to Anti-MET Drugs
- Mitigation of Tumor-Associated Fibroblast-Facilitated Head and Neck Cancer Progression with Anti–Hepatocyte Growth Factor Antibody Ficlatuzumab
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- Immunology and Immunotherapy of Head and Neck Cancer Robert L
- Anti-Alphavbeta3 Monoclonal Antibody EMD 525797 (CUI C2830088) Add to Cart
- Immunotherapy of Head and Neck Cancer: Summary of a National Cancer Institute Head And
- Focus on the Potential Role of Ficlatuzumab in the Treatment of Non-Small Cell Lung Cancer
- WO 2015/038782 Al 19 March 2015 (19.03.2015) P O P C T
- Current Advances of Targeting HGF/C-Met Pathway in Gastric Cancer
- Cancer PRESENTEDBYAMERICA ’ SBIOPHARMACEUTICALRESEARCHCOMPANIES Nearly 900 Medicines and Vaccines in Testing Offer Hope in the Fight Against Cancer
- WO 2013/119960 A2 15 August 2013 (15.08.2013) P O P C T
- (INN) for Biological and Biotechnological Substances
- Preclinical Efficacy of the Anti-Hepatocyte Growth Factor Antibody Ficlatuzumab in a Mouse Brain Orthotopic Glioma Model Evaluated by Bioluminescence, PET, and MRI
- Oncology Drugs in the Pipeline
- (EGFR) Antibodies in Squamous Cell Carcinoma of the Head and Neck
- A Randomized, Phase II Study of Ficlatuzumab With
- (AV-299), an Anti-Hepatocyte Growth Factor Monoclonal Antibody, In
- A Pharmacodynamic/Pharmacokinetic Study of Ficlatuzumab in Patients with Advanced Solid Tumors and Liver Metastases
- Comprehensive Review of Targeted Therapy for Colorectal Cancer
- The Potential Roles of Hepatocyte Growth Factor (HGF)-MET Pathway Inhibitors in Cancer Treatment
- Therapeutic Application of Monoclonal Antibodies in Pancreatic Cancer: Advances, Challenges and Future Opportunities
- Cmet Axis in Cancer Therapy